The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …

With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …

The classification of myeloid neoplasms and acute leukemias was last updated in 2016
within a collaboration between the World Health Organization (WHO), the Society for …

Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to≥ 2
tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of …

Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic
cells driven by somatic gene mutations. Although assessment of morphology plays a crucial …

In the ENESTnd study, with≥ 10 years follow-up in patients with newly diagnosed chronic
myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Abstract The Worldwide Network of Blood and Marrow Transplantation (WBMT) pursues the
mission of promoting hematopoietic cell transplantation (HCT) for instance by evaluating …

Abstract In PACE (Ponatinib Ph+ ALL and CML Evaluation), a phase 2 trial of ponatinib that
included patients with chronic-phase chronic myeloid leukemia (CP-CML) resistant to …

Asciminib, the first BCR:: ABL1 inhibitor that S pecifically T argets the A BL M yristoyl P ocket
(STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome …